<p>This is a multi-center, randomized, double-blind, placebo-controlled trial of CoQ involving 609 ambulatory subjects with HD who are not requiring skilled care or institutionalization. Eligible subjects were randomized to receive either CoQ 2400 mg/day or matching placebo. Subjects were followed prospectively and systematically for 60 months of double-blind observation. The primary outcome variable is a combination of time to death (for subjects who die) and the change from baseline to Month 60 in Total Functional Capacity (TFC) score (for subjects who survive). The primary hypothesis of the study is that chronic treatment of early-stage HD subjects with high-dosage CoQ will slow the progressive functional decline of HD.</p>

Coenzyme Q10 (CoQ) in Huntington's Disease (HD) (2CARE)

735 variables across Anthropometry, Biomarkers, Demographics + 8 more

Coenzyme Q10 (CoQ) in Huntington's Disease (HD) (2CARE)

Anthropometry (2)

Biomarkers (10)

Demographics (19)

Disease Events (4)

General Health (12)

Geography (1)

Imaging (8)

Medications (9)

Mental Health (41)

Race and Ethnicity (12)

Substance Use (4)

Other (613)